Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA.

PaperCitations, authors & open-access status

Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA. is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 14 citations, 2019 year and closed oa status.

14
Citations
2019
Year
closed
OA Status

Related on ScholarIQ

Caroline McKay
Author
Journal of Clinical Oncology
Journal
Multiple Myeloma Research and Treatments
Topic
Multiple Myeloma Research and Treatments
Topic
Cancer Treatment and Pharmacology
Topic
Statistical Methods in Clinical Trials
Topic
470M+ articles · free account